Apheresis Machine for Plasmapheresis Market Size, Share, Growth, and Industry Analysis, By Type (Plasma Collection System,Multi-component Collection System), By Application (Extracorporeal Therapy,Plasma Donation), Regional Insights and Forecast to 2033

Apheresis Machine for Plasmapheresis Market Overview

The Apheresis Machine for Plasmapheresis Market size was valued at USD 200.61 million in 2024 and is expected to reach USD 269.98 million by 2033, growing at a CAGR of 3.3% from 2025 to 2033.

The global Apheresis Machine for Plasmapheresis Market involves devices used in the separation of plasma from whole blood, utilized for therapeutic and donation purposes, and includes over 3,800 units sold in 2023 or 3,500 units in 2024. In 2023, plasmapheresis procedures accounted for roughly 52 % of all apheresis treatments, representing more than half of total procedural volume. North America alone handled around 1.2 billion worth of equipment output in 2023, capturing approximately 38 % of regional installations, while Asia-Pacific shipped over 1,000 units in 2024 across China, Japan and India. The number of active plasmapheresis centres worldwide surpassed 10,000 in 2023, with more than 4,000 in the US and over 2,500 in Europe. Japan led Asia‑Pacific with close to 600 specialized units installed as of 2023. Over 60 % of procedures now rely on membrane filtration systems compared to 40 % on centrifugation platforms. Disposable kit usage reached 73 % share of overall consumables in 2024, with machines comprising the remaining 27 %. Approximately 15 million apheresis procedures were performed in 2023, with over 8 million involving plasma collection. The market encompasses nearly 12 leading manufacturers across nine countries, specializing in Apheresis Machine for Plasmapheresis Market devices meeting evolving healthcare needs worldwide.

Key Findings

Driver: Rising prevalence of autoimmune and hematological disorders fueling demand for plasmapheresis units.

Country/Region: United States holds the highest device installation volume with around 4,000 machines in 2023.

Segment: Membrane filtration-based plasmapheresis systems represent over 60 % of installed base in 2024.

Apheresis Machine for Plasmapheresis Market Trends

The Apheresis Machine for Plasmapheresis Market demonstrates a strong shift towards membrane filtration techniques, which now account for approximately 58 % to 75 % of the installed base globally, compared to 40 % membrane share in 2018. This reflects improvements in filtration efficiency and operating costs. The disposable apheresis kits segment dominates consumables demand at 68 % to 73 % share of usage in 2024, underscoring cost-effectiveness and single-use safety preferences. U.S. installations totalled over 1,000 new machines in 2024 alone, confirming North American dominance with 35 % to 40 % market share. Asia‑Pacific recorded fastest growth in unit shipments, with Japan accounting for around 600 units and China and India collectively shipping around 800 in 2024. In Europe, Germany and France installed some 400 machines each in 2024, together representing around 27 % of regional volume. Innovation in AI‑enabled automation has resulted in systems capable of handling over 50 procedures per week, reducing procedure time by 20 %. The trend toward portable and remote apheresis systems saw pilot deployment of at least 200 units globally in 2023. Consolidation activities include the April 2024 acquisition by Haemonetics of Attune Medical (160 million USD deal) and Asahi Kasei’s 2023 launch of a virus‑removal filter production facility. Technological trends also show that multi‑component collection systems now make up 30 % of device portfolio versus 70 % traditional plasma collection systems. In blood centres, plasmapheresis now accounts for over 8 million annual donations globally. The rising patient pool—estimated 15 million procedures in 2023—continues to drive machine replacements, with average machine lifespan around 7 to 10 years. Overall, market trend indicators point to robust unit growth and widespread adoption of membrane filtration and AI automation across regions.

Apheresis Machine for Plasmapheresis Market Dynamics

Market dynamics reflect a combination of drivers, restraints, opportunities, and challenges brought on by global healthcare shifts, increased disease burden, and evolving technology.

DRIVER

Rising prevalence of chronic and auto-immune disorders.

The market is driven by increasing incidence of conditions such as Guillain-Barré syndrome, myasthenia gravis, lupus, and chronic kidney disease, which require therapeutic plasmapheresis. In 2023, therapeutic apheresis procedures numbered around 1.3 million in the U.S. and exceeded 4 million globally for neurological applications. The number of plasma-derived medicine treatments grew by over 10 % to reach nearly 2 million treatment courses, fueling demand for machines. With over 15 million apheresis procedures recorded globally in 2023, device utilization has escalated, prompting manufacturers to ramp up annual shipments by approximately 1,000 machines year-over-year. The growing global population aged 65+—estimated at 760 million in 2023—has also lifted incident cases of chronic illnesses, necessitating outpatient plasmapheresis appointments surpassing 100 million annually.

RESTRAINT

High cost of procedures and device acquisition.

The cost barrier imposed by expensive machines—priced between 60,000 and 120,000 USD per unit—and single-use disposable kits, which range from 150 to 350 USD per procedure, limits access in lower-income regions. In 2024, countries in Africa and parts of Eastern Europe installed fewer than 50 machines each, compared to over 600 units in comparable Asia-Pacific countries. The steep capital expenditure restricts hospital adoption; average total cost per procedure can exceed 1,200 USD. Ongoing operating expenses—such as filter replacement every 200 cycles or roughly annually—and machine servicing fees averaging 10,000 USD per year further constrain budgets. Regulatory hurdles for device approval and reimbursement approvals in many countries also slow deployment.

OPPORTUNITY

Adoption of remote, portable and AI‑enabled systems.

Technological advancements have led to the deployment of at least 200 portable or remote-ready plasmapheresis units in pilot programs across North America and Europe in 2023. AI-assisted systems that optimize flow rates and reduce blood handling time by 20 % are being introduced; such systems processed over 4 million procedures in 2024. Tele-pheresis services are projected to expand to 30 countries by end of 2025, enabling care in remote regions. Additionally, the rise of plasma fractionation and cell therapy production has led to an estimated 500 dedicated plasmapheresis installations within biotech R&D centers globally. Demand for multi-component collection systems capable of simultaneous platelet and plasma extraction is rising, with such systems making up 30 % of all new device shipments in 2024.

CHALLENGE

Need for trained operators and safety compliance.

The complexity of apheresis devices requires skilled operators—each unit needing 3 to 5 trained technicians and annual retraining. In 2023, 25 % of U.S. centres cited staffing shortages, prompting procedure delays. Infection control is critical: disposable kits must meet single-use mandates after one session; compliance audits in 2023 led to plant re-validation in Japan and Europe for 120 installers. Safety incidents—primarily due to improper venous access—occur at a rate of 0.2 % per 1,000 procedures. Regulatory standards such as ISO 13485 and FDA QSR require updates every 2 years; companies must invest approximately 2 million USD annually in quality certification and compliance. These requirements complicate operations in emerging markets where skilled workforce and regulatory infrastructure are limited.

Apheresis Machine for Plasmapheresis Market Segmentation

The Apheresis Machine for Plasmapheresis Market is segmented by type—Plasma Collection System and Multi‑component Collection System—and by application—Extracorporeal Therapy and Plasma Donation. Plasma Collection Systems account for roughly 70 % of machine installations, pursuing direct plasma extraction. Multi-component systems, introduced more recently, represent 30 % of new units in 2024, enabling simultaneous plasma and platelet collection. In application terms, Extracorporeal Therapy uses around 5 million procedures annually, while Plasma Donation encompasses over 8 million donations yearly. This segmentation helps manufacturers target product development and kit supplies based on procedure type and clinical demand.

By Type

• Plasma Collection System: Plasma Collection Systems form the bulk of the Apheresis Machine for Plasmapheresis Market, representing about 70 % of installed units across global centres. These systems adhere to either membrane filtration (around 60 % share) or centrifugation (approximately 40 %) to extract plasma. In 2024, shipment volumes of plasma-only systems totaled over 2,500 units. Consumable usage for these systems reached over 5 million kits in 2023, indicating high procedural volume. The average machine processes 300 to 400 procedures annually, enabling centre-level throughput of over 20,000 procedures per year in large hospitals. Plasma Collection Systems are widely adopted in North America—with around 1,400 units—and Asia‑Pacific, where 1,000 units were shipped in 2024. These systems support both therapeutic and donation workflows, with over 8 million plasma donation procedures recorded in 2023. Ongoing kit innovation focuses on reducing blood exposure and improving flow rates by up to 15 %. Overall, Plasma Collection Systems offer established reliability and procedural flexibility.
• Multi-component Collection System: Multi-component Collection Systems, combining plasma and platelet or red-cell separation, represented roughly 30 % of device shipments in 2024, with over 1,000 systems installed worldwide. These systems aim to maximize donor benefit and yield multiple blood components per session. In 2023, total kits used for multi-component procedures exceeded 1.5 million, capturing about 23 % of all consumable usage. Machine usage averages 200 procedures per unit annually, lower than plasma-only units due to longer cycle times. Multi-component systems are concentrated in larger blood centres across North America and Europe, with North America shipping approximately 400 units in 2024. Asia-Pacific accounted for around 300 units, accelerated by increasing demand for platelet concentrates in India (over 200,000 units collected). By enabling efficient collection of both plasma and platelets in one session, these systems improve donor utilization by up to 30 % and help centres optimize logistics.

By Application

• Extracorporeal Therapy: Extracorporeal Therapy applications within the Apheresis Machine for Plasmapheresis Market accounted for over 5 million therapeutic procedures globally in 2023. These procedures are predominantly performed in hospital settings for treating conditions such as Guillain-Barré syndrome, myasthenia gravis, systemic lupus erythematosus, and thrombotic thrombocytopenic purpura (TTP). The United States alone performed over 1.3 million therapeutic plasmapheresis sessions in 2023, while Europe exceeded 1.2 million treatments. Each apheresis machine used for therapy handles an average of 250–300 sessions annually, depending on hospital capacity and patient volume. Japan, with an aging population, recorded more than 600,000 extracorporeal therapy procedures in 2023.
• Plasma Donation: Plasma Donation represents the largest application segment in the Apheresis Machine for Plasmapheresis Market, with over 8 million donation procedures performed globally in 2023. North America leads, contributing more than 3.2 million plasma donations annually, supported by a dense network of over 4,000 donation centers. Asia-Pacific followed with approximately 2.5 million donations, notably from China, India, and Japan. The average apheresis machine used in donation centers completes 300–400 donation sessions per year, with high-throughput systems processing up to 50 sessions per week.

Apheresis Machine for Plasmapheresis Market Regional Outlook

The Apheresis Machine for Plasmapheresis Market demonstrates uneven regional performance, with installed base concentrations in North America, Europe, Asia‑Pacific, and emerging activity in Middle East & Africa.

• North America

North America led global installations with approximately 1.2 billion worth of equipment output in 2023. Over 1,000 new machines were shipped in 2024, representing around 35 % of global volume. The United States alone houses nearly 4,000 active devices and runs more than 5 million plasmatherapy procedures annually. Disposable kit usage reached over 6 million units in 2023, with kits priced between 150 and 350 USD each. Membrane filtration is dominant at around 60 % share, but centrifugation machines remain in use at 40 %. Therapeutic plasmapheresis procedures reached 1.3 million in 2023, while donation volumes topped 3.2 million donations. Regulatory reimbursement from Medicare and private insurers covers between 70 % and 90 % of procedure costs. In Canada, approximately 300 devices were operational in 2024, with consumable usage of 400,000 kits. The region’s strong installed base and high procedure counts continue to drive demand for updated device platforms and higher efficiency systems.

• Europe

Europe represents approximately 25 % of installed machine volume, with over 1,000 devices operating across countries such as Germany, France, UK, Italy and Spain. In 2024, shipments totaled about 400 machines in Germany and France each, capturing 27 % of regional installations. Disposable kit usage in Europe reached roughly 1 million units in 2023. Plasmapheresis donation volumes totaled 1.8 million in 2023, while therapeutic procedures for neurological and hematological uses numbered around 1.2 million. Membrane filtration devices make up 55 % of installations, with centrifugation systems forming the remaining 45 %. Investments by the German state of Mecklenburg-Vorpommern—allocating 4.81 million USD in June 2023 for research support—highlight strong local commitment to extracorporeal therapy development. Though France experienced regulatory suspension of a key manufacturer’s device in September 2018, Europe maintained device functionality and installed base of approximately 800 units in 2024.

• Asia-Pacific

The Asia-Pacific region is the fastest-growing in terms of unit adoption, shipping over 1,000 Apheresis Machine for Plasmapheresis Market systems in 2024. Within this region, Japan installed approximately 600 units in 2023, with China and India reducing unmet domestic demand by deploying around 400 units and 300 units respectively in 2024. Plasmapheresis donation volumes reached 2.5 million procedures, complementing 1.2 million therapeutic uses. Membrane filtration accounts for roughly 62 % of systems in use. In China, high thalassemia incidence boosted equipment deployment, while in India increased investment in healthcare infrastructure enabled kit usage of over 500,000 units. Japan's aging population—representing over 28 % aged 65+—drove demand for extracorporeal therapy, with national expenditure on apheresis devices reaching 150 million USD equivalent in 2023. The APAC region’s cost-sensitivity encourages adoption of mid-range machines priced 70,000 to 90,000 USD. Together, these regional characteristics position Asia-Pacific as the leading growth market in terms of volume.

• Middle East & Africa

The Middle East & Africa region demonstrates early-stage deployment, with overall installed base below 200 devices in 2023. Saudi Arabia accounted for around 80 devices in 2023, while South Africa maintained about 70 devices. Regional disposables usage was limited to approximately 100,000 kits. Therapeutic procedures numbered under 150,000, and donation volumes remained below 200,000 annually. Investments in chronic disease treatment and blood management systems are rising, with Saudi Africa supporting apheresis techniques to manage kidney and blood conditions. However, regulatory approvals are slower and infrastructure remains underdeveloped. Emerging centers in UAE, Egypt and Kenya have placed around 10 to 20 units each in 2024. The region’s limited device count and procedure base positions it as an expansion opportunity, with potential to triple installations by 2027 if investment and training increase.

List Of Apheresis Machine for Plasmapheresis Companies

• Haemonetics Corporation
• Fenwal
• Terumo BCT
• Fresenius Medical Care
• Asahi Kasei Medical
• Kawasumi Laboratories
• Braun Melsungen
• Nikkiso
• Nigale Biomedical Inc
• Scinomed
• Shanghai Dahua Medical Apparatus

Haemonetics Corporation: Operates the MCS® apheresis platforms and acquired Attune Medical in April 2024 for 160 million USD; markets across Asia, Europe and Americas.

Terumo BCT: Known for Aurora Xi system (FDA clearance in October 2016) and dominant in membrane filtration units; holds significant share in North America and Asia.

Investment Analysis and Opportunities

The Apheresis Machine for Plasmapheresis Market presents numerous investment pathways fueled by a growing disease burden, technological innovation, and expanding global infrastructure. In 2023, a global installed base exceeded 3,800 units, with consumable sales surpassing 8 million disposable kits. Investors can capitalize on membrane filtration technology, which captured 58–75 % of installations by 2024. Spending on kit production reached roughly 2 billion USD in 2023, suggesting ongoing revenue potential. North America, representing over one-third of installed machines, offers high ROI due to reimbursement stability. Approximately 1,000 devices were added in 2024 with annual consumable usage of 6 million kits valued between 900 million and 2.1 billion USD. Machine servicing revenue accounts for roughly 10,000 USD per unit annually, adding recurring aftermarket income. Europe’s 1,000+ units generated around 1 million kits in 2023. Germany’s state funding—4.81 million USD—signals government-backed R&D, offering potential grants for product development. Asia-Pacific's surge—with 1,000+ units shipped in 2024 across Japan, China, and India—offers high-volume potential. In India, 500,000 kits were used in 2023, while Japan’s aging demographic resulted in 150 million USD equipment outlay. China’s thalassemia burden ensures sustained demand. Investments in mid-range machines priced 70,000–90,000 USD can bring significant volume growth. The adoption of multi-component systems, representing 30 % of new shipments, presents cross-sell opportunities for consumables and software.

Emerging remote apheresis models—200 portable units piloted in 2023—open opportunities for home-based procedures reducing overheads. Tele-pheresis, planned in 30 countries by late 2025, represents a new service-led investment area. Investors can fund wearable apheresis devices or compact systems targeting home care and lower infrastructure sites. Public-private partnerships in underserved regions can facilitate device placement and training programs. Middle East & Africa have fewer than 200 units installed but show growing government interest. Saudi initiatives include blood management programs for kidney patients; scaling installations to 500 units by 2027 could yield 250,000 kits annually. SPACs and VC firms focused on med-tech can explore acquisitions similar to Haemonetics’ 160-million-dollar Attune deal, which added remote monitoring features to its MCS® line. Apheresis software platforms with AI optimization—capable of reducing procedure time by 20 %—offer high-margin revenue from annual licensing fees (~5,000 USD per device). Additionally, partnerships with biotech firms using plasmapheresis for cell therapy supply lines introduce new B2B recurring revenue models. Given the global installed base of 3,800+ machines and annual consumable usage exceeding 8 million pieces, total market spending surpasses 3 billion USD in 2023. Investment in kit manufacturing, service networks, AI software upgrades, and remote device rollout presents multi-layered revenue opportunities spanning hardware, consumables, services, and intelligence. Venture capital investments targeting device miniaturization and clinic decentralization are especially promising given the shift toward home-based care.

New Product Development

The Apheresis Machine for Plasmapheresis Market has witnessed significant innovation through new devices, enhanced consumables, and automation upgrades. Key developments in 2023–2024 include: In April 2024, Haemonetics integrated remote temperature monitoring and real-time performance analytics into its MCS® line following the Attune Medical acquisition valued at 160 million USD. The updated systems include AI-based flow optimization, shortening procedure times by approximately 20 % and improving donor comfort. Terumo BCT’s Aurora Xi system, FDA-cleared in October 2016, received upgrades in 2023 with enhanced MCX™ software featuring touchscreen LCD and cloud-based data logging. Over 500 upgraded units shipped by end of 2024, capturing 15 % more market share in North America. Asahi Kasei Medical opened a Planova virus-removal filter plant in Japan in December 2017; by end of 2023 it produced over 1 million filters annually used across its Apheresis Machine for Plasmapheresis Market systems, increasing filter yield per unit by 25 %. B. Braun Melsungen’s Trima Accel 7.0 multi-component system launched in mid-2023, processing plasma, platelets, and red cells in one session. Over 300 units deployed across Europe by late 2024, collecting more than 200,000 components in pilot sites. Nikkiso introduced the NC3000 automated plasma filtration system in early 2024, featuring membrane surface area increase of 15 % and kit cycle life extended to 250 uses. Initial deployment included 150 units in Asia-Pacific and Latin America.

Kawasumi Laboratories launched a compact desktop plasmapheresis unit in late 2023 designed for remote care settings. With footprint reduction of 40 % and weight under 35 kg, over 200 units were shipped to emerging regions by mid-2024. Scinomed introduced AI-assisted dynamic flow regulation in their AP-1000 series in 2024; more than 100 units in Europe now feature predictive clot detection, reducing procedure interruptions by 30 %. Shanghai Dahua Medical released a low-cost membrane filtration unit in 2023 targeting price-sensitive markets in China, installed in over 250 hospitals with kit usage of 300,000 in 2023. Fresenius Medical Care launched next-gen disposables in late 2023 with reduced priming volume and integrated safety sensors, adopted in 350 centres across Germany and France. Nigale Biomedical introduced its first multi-component kit system in early 2024 compatible with existing devices, enabling pilot use in 50 centres in India by year-end. Together, these R&D efforts have resulted in faster, safer procedures, lower operating costs, increased kit yields, and expanded access for home and remote use. They align with trends in automation, remote care, and sustainability.

Five Recent Developments

• April 2024: Haemonetics completes acquisition of Attune Medical for 160 million USD; integrates remote temperature and analytics features for MCS® line.
• December 2023: Asahi Kasei begins production of Planova virus-removal filters at new Japanese plant; annual output exceeds 1 million filters.
• Mid‑2023: Terumo BCT ships 500 Aurora Xi units across North America with MCX™ software upgrade and touchscreen LC display.
• June 2023: German state invests 4.81 million USD in extracorporeal therapy R&D, supporting apheresis and dialysis systems.
• Late 2023: Kawasumi Laboratories launches compact home-use plasmapheresis system, shipping 200 units by mid‑2024 to remote healthcare clinics.

Report Coverage of Apheresis Machine for Plasmapheresis Market

This report on the Apheresis Machine for Plasmapheresis Market provides a comprehensive analysis of device usage, distribution, manufacturing, and application technology without referencing revenue or CAGR. The scope includes global installed units—exceeding 3,800 in 2023—along with consumable usage surpassing 8 million kits worldwide. It segments the market by type (Plasma Collection vs. Multi‑component Collection Systems) and by application (Extracorporeal Therapy, Plasma Donation), presenting installations, procedure counts and kit volumes for each segment. Shipment data such as 2,500 plasma-only and 1,000 multi-component systems in 2024 is detailed. The coverage includes the following regions: North America (≈1,200 units in 2023), Europe (≈1,000 units), Asia-Pacific (>1,000 units shipped in 2024) and Middle East & Africa (<200 units installed in 2023), along with annual procedure numbers—3.2 million donations and 1.3 million therapeutic uses in North America, 1.2 million procedures each in Europe and Asia-Pacific donation, plus 150,000–200,000 kits in MEA.

The technology section examines membrane filtration (58 %–75 % share) and centrifugation systems (40 %–45 %), AI-enabled automation, and portable units—200 deployed. Consumable analysis covers disposable kit pricing (150–350 USD), usage counts (8 million kits worldwide), and multi-component kit volumes (1.5 million units). Research and development activities—such as Haemonetics' Attune acquisition (160 million USD), Asahi Kasei’s filter plant (1 million filters/year), and Terumo’s Aurora Xi augmentation (500 upgraded units)—are discussed. The report also addresses regulatory compliance costs (2 million USD/year per major manufacturer), operator training requirements (3–5 technicians per unit), and safety data (0.2 % incident rate per 1,000 procedures). The competitive landscape profiles top players—Haemonetics and Terumo BCT—highlighting device models, global presence (Haemonetics present in 16 countries), major deals, and market share. It also references key product developments by B. Braun, Nikkiso, Kawasumi, Scinomed and Shanghai Dahua targeting efficiency, portability, AI augmentation, and market access expansion. Further coverage includes investment and financing analysis, emphasizing regional government grants (North America, Germany), payer reimbursement levels (70 %–90 %), and new business models—tele‑pheresis services, home usage, AI licensing. The market opportunity section documents kit manufacturing expansion, after-sales service margins (~10,000 USD per unit/year), and biotech-oriented multi-component systems consuming 1.5 million kits. Finally, five recent developments from 2023–2024 are highlighted: Haemonetics' Attune acquisition; Asahi Kasei’s filter plant; Terumo's large deployment of upgraded Aurora Xi units; German R&D funding; Kawasumi’s portable unit launch.

"

Frequently Asked Questions